Recombinant factor VIIa (rFVIIa) may be useful in management of severe bleeding in paediatric oncology patients. We described our experience and outcomes in a form of a case series. In all cases, indication was massive gastrointestinal bleeding with haemodynamic instability, persistent thrombocytopenia and coagulopathy despite correction. The range of doses used was 88-102 mcg/kg/dose. Each patient received at least 3 doses. The use of rFVIIa resulted in a reduction in blood product support requirement. rFVIIa was effective in 2 out of 3 patients in stopping the bleeding. There were no drug-related complications. rFVIIa has a critical role to play in the early management of severe bleeding in critically ill paediatric oncology patients.
IntRodUCtIon
Recombinant factor VIIa (rFVIIa, NovoSeven®; NovoNordisk) is a novel haemostatic agent principally licensed to treat bleeding episodes in haemophilia A and B patients with inhibitors. In some jurisdictions, it is also approved for use in patients with factor VII deficiency, Glanzmann's thrombasthenia and the management of post surgical bleeding 1 . Because it acts at the site of tissue injury via interactions with tissue factors and activated platelet surfaces to propagate clot formation, it has the potential to be a universal haemostatic agent and has been keenly tried in an "off label" fashion in patients with refractory bleeding from various other situations such as cardiac surgery, trauma and post-partum bleeding. Until recently most of these reports have been confined to adult populations but increasingly, larger paediatric series are being reported, including in critically ill patients with sepsis and disseminated intravascular coagulation. Unfortunately, overall outcomes in such patients are dismal. In our institution, we are building on our experience with rFVIIa and have used this in similar situations with varied outcomes. In this report we appraised our experience with the use of this novel agent in the management of gastrointestinal bleeding in 3 critically ill non-haemophiliac patients with underlying malignancy. The aim of this exercise is to carefully relate patient characteristics and preinfusion parameters and other interventions in this group of paediatric patients to best understand reasons for their varied outcomes. This retrospective review was approved by our hospital's institutional review board.
CASE #1
A 9-year-old boy with relapsed Burkitt's lymphoma was intubated for respiratory distress secondary to malignant pleural effusion. Chemotherapy was started but this was complicated by septic shock and acute renal failure requiring citrate-based continuous haemodialysis. He then developed Proceedings of Singapore Healthcare  Volume 19  Number 2  2010 upper gastrointestinal (GI) bleeding with hypotension. Following initial fluid resuscitation, blood products were transfused as shown in Table 1 . Despite this, the GI bleeding persisted and he was too unstable for any surgical or endoscopic assessment and intervention. Three doses of rFVIIa were then given at 90mcg/kg/dose 3 hours apart. The full blood count and coagulation profile before and after the use of rFVIIa is shown in Table 1 . There was a marked reduction in blood product support following the use of rFVIIa. The amount of bleeding from nasogastric tube aspirate was reduced from 400mls (15ml/kg) in the first 5 hours of bleeding to 50mls (2ml/kg) over the following 24 hours. There were no clot formation in the haemodialysis filter and no thromboembolic complications. Although he recovered from the GI bleed, he died of his disease after a stay of more than a month.
CASE #2
A 7-year-old girl with relapsed acute lymphoblastic leukaemia was found to have coffee ground vomitus and melena on the 2nd day of commencing salvage chemotherapy with an L-asparaginase -based protocol. Four days later, this progress into a profuse fresh per rectal (PR) bleeding with hypotension. Large volume blood product transfusion ( Table 1) was given together with fluid resuscitation. She unfortunately required intubation for pulmonary oedema secondary to volume overload precipitated by the initial resuscitative efforts. Despite transfusion of the blood products, PR bleeding persisted, triggering a decision to use rVIIa 4 ½ hours after the first evidence of active PR bleeding. Table 1 shows her full blood count and coagulation profile. After the first dose of rVIIa, she was haemodynamically stable enough for an emergency laparotomy. This revealed diffuse bleeding from a possible source at the 2nd and 3rd part of the duodenum. Despite application of surgical sutures to these areas, slow generalised oozing continued. A second dose of rFVIIa was therefore given intra-operatively. A total of 4 doses at 90mcg/kg/dose were given over a period of 9 hours. Transfusion requirements were markedly reduced after rFVIIa was administered. There were no thromboembolic complications. She recovered from the haemorrhagic episode and was discharged well after 16 days. 
CASE #3
A 3-year-old girl with medulloblastoma was admitted for febrile neutropenia secondary to coagulase-negative staphylococcus bacteremia and trichosporon fungemia. Her condition deteriorated into septic shock with coagulopathy and acute renal impairment requiring peritoneal dialysis. This was complicated by fresh PR bleeding which did not abate with blood product transfusion. Threeand-a-half hours after the onset of bleeding, rFVIIa was started. Surgical intervention was not possible due to her clinical instability. A total of 3 doses of 100mcg/kg/dose were given over a period of 10 hours in view of ongoing bleeding. There was only fair resolution of bleeding with small amount of blood clots noted per rectum and stale blood coming from the nasogastric tube. Disseminated intravascular coagulopathy (DIC) screen in this patient was positive. D-dimer was 2ug/mL; soluble fibrin and fibrinogen levels was 3.5umol/L. There was no reduction in volume of blood product used before and after rFVIIa was started. She subsequently died of overwhelming sepsis after 12 days.
dISCUSSIon
An important cause of morbidity and mortality in children with malignancies is bleeding. This commonly occurs in the setting of treatment related profound thrombocytopenia, coagulopathy and sepsis. Conventional treatment by appropriately addressing surgical bleeding and transfusion of appropriate blood products should be the first line strategy in securing haemostasis. These measures are, unfortunately, inadequate in some patients with torrential or microvascular bleeding, which may be further compounded by underlying platelet refractoriness from repeated transfusions. Critically ill patients may also be haemodynamically too unstable to tolerate surgical or endoscopic procedures. rFVIIa, which has been touted as a potential "universal" haemostatic agent, is therefore particularly attractive to physicians in such a therapeutic dilemma. In children with malignancies and bleeding, its value has been described in brief reports incorporated in small case series with variable dosing strategies and responses 2,3 .
There is currently no universally accepted standard to monitor the efficacy of rFVIIa. A European consensus recommends that the efficacy be monitored visually and according to reductions in transfusion requirement 4 . Using such recommended criteria, the responses to rFVIIa among our 3 patients had been varied and was considered to be effective in 2 of the 3 patients treated. A critical appraisal of our experience with rFVIIa in these cases revealed several clinically relevant observations. Adequate correction of any underlying coagulopathy or thrombocytopenia is likely paramount for effective response to rFVIIa. A better outcome would likely have been achieved had we been more aggressive in replacing fresh frozen plasma and cryoprecipitate in Case #3, prior to using rFVIIa. In contrast, Case #2 was given significantly greater volumes of fresh frozen plasma for a similar deranged coagulation profile and achieved an adequate treatment response with rFVIIa. Case #2 also illustrated the value of rFVIIa in a situation where surgical solutions and blood product transfusion had been optimised but were inadequate to resolve microvascular bleeding.
Overwhelming sepsis that eventually led to the demise of Case #3 was responsible for ongoing consumption coagulopathy which may have rendered rFVIIa less effective in securing adequate haemostasis, without appropriate correction. In retrospect, the prevailing coagulation profile and clinical condition of this patient would have predicted a poor response to rFVIIa. Fibrinogen levels would have been useful in guiding the use of cryoprecipitate but rapid test results were unfortunately not available to us during the acute management of these 3 cases.
The need for repeated dosing to successfully secure haemostasis in our patients should provide the impetus for considering the role of higher initiating doses than the standard 90mcg/kg that we used. Indeed, there is evidence that increased metabolism and volume of distribution in children may entail requirements for higher and more frequent doses 5, 6 . Doses of up to 240mcg/kg have reportedly been used 3 . "Megadosing", as similarly proposed in the treatment of haemophilia patients, should be the subject of further studies before it can be recommended for critical bleeding as in our patients. A step-wise incremental dosing approach could also be adopted in a patient failing adequate response such as our third patient. It is however essential to stress that a failure to response to initial therapy should prompt the attending clinician to reassess and address predictors of poor response such as surgical bleeding, uncorrected thrombocytopenia, coagulopathy as well as hypothermia and acidosis [7] [8] [9] . Nevertheless, a Proceedings of Singapore Healthcare  Volume 19  Number 2  2010 complete assessment for surgical bleeding sites within the gastrointestinal tract can be a great challenge in critically ill children.
Our local experience with these 3 patients is fairly comparable to a much larger retrospective off-label study involving children with excessive bleeding. In this study of 139 children from 1999-2005, the authors used a similar indication of starting rFVIIa (only when standard measures to control bleeding were undertaken) and similar methods to judge efficacy (3-point scale supported by measurement of transfusion of blood products 3 days prior and following the use of rFVIIa) 10 . This study however, involved a heterogeneous group of patients with multiple background medical problems and various bleeding sites. Taking the subgroup of abdominal bleeding, their response is excellent in about 60% of their patients and ineffective in 13% 10 . Our results are fairly similar with 2 out of 3 patients where rFVIIa was effective.
Another important consideration in using rFVIIa is the cost-effectiveness of the therapy. The cost of one vial of rFVIIa (1.2mg) locally is $1,421. Based on the dosing regime used in our series of patients, the cost of administration ranges from $4,263-8,500. This cost must be borne in mind when weighing the possible therapeutic options in such cases.
Through this case series, we sought to illustrate the value and potential pitfalls of using rFVIIa in children with malignancies complicated by GI haemorrhage that were not amenable to conventional haemostatic measures. Serious side effects such as thromboembolic events should be actively considered and looked out for in all patients who are given rFVIIa. It is our belief that rFVIIa has a critical role in the management of such patients. However, an understanding of the optimal conditions for its actions and its limitations will ensure that the most appropriate patients are treated with this costly agent with more predictable good outcomes.
